Evidence map›Paper›PMID 39030949›Full record

ArticleMovement disorders clinical practice2024

Improving Parkinson's Disease Care through Systematic Screening for Depression.

Connie Marras, Zachary Meyer, Hongliang Liu, Sheng Luo, Sneha Mantri, Allison Allen, Sydney Baybayan, James C Beck, Amy E Brown, Francis Cheung and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Movement disorders clinical practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Perspective: Depression in Persons with Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Connie MarrasThe Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Center, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0002-9236-9328
Zachary MeyerParkinson's Foundation, New York, New York, USA.
Hongliang LiuDepartment of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina, USA.
Sheng LuoDepartment of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina, USA.ORCID https://orcid.org/0000-0003-4214-5809
Sneha MantriDepartment of Neurology, Duke University School of Medicine, Durham, North Carolina, USA.ORCID https://orcid.org/0000-0003-4556-0522
Allison AllenDepartment of Neurology, Duke University School of Medicine, Durham, North Carolina, USA.
Sydney BaybayanDepartment of Neurology, The Parkinson's Disease and Movement Disorders Center, Johns Hopkins University, Baltimore, Maryland, USA.
James C BeckParkinson's Foundation, New York, New York, USA.
Amy E BrownDepartment of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Francis CheungDivision of Neurology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Nabila DahodwalaDepartment of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
Thomas L DavisDepartment of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Megan EngelandDepartment of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
Conor FearonThe Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Center, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Nicole JonesDepartment of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Kelly MillsDepartment of Neurology, The Parkinson's Disease and Movement Disorders Center, Johns Hopkins University, Baltimore, Maryland, USA.ORCID https://orcid.org/0000-0002-4302-1501
Janis M MiyasakiDivision of Neurology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.ORCID https://orcid.org/0000-0002-6372-6007
Anna NaitoParkinson's Foundation, New York, New York, USA.
Marilyn NeaultParkinson's Foundation, New York, New York, USA.
Eugene C NelsonDepartment of Community and Family Medicine at Geisel School of Medicine at Dartmouth College, The Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, New Hampshire, USA.
Ebubechukwu OnyinanyaDepartment of Neurology, The Parkinson's Disease and Movement Disorders Center, Johns Hopkins University, Baltimore, Maryland, USA.
Carlos RopaThe Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Center, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Daniel WeintraubDepartments of Psychiatry and Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.ORCID https://orcid.org/0000-0003-0633-7168

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDepression is common in Parkinson's disease (PD) but is underrecognized clinically. Although systematic screening is a recommended strategy to improve depression recognition in primary care practice, it has not been widely used in PD care.

methodsThe 15-item Geriatric Depression Scale (GDS-15) was implemented at 5 movement disorders clinics to screen PD patients. Sites developed processes suited to their clinical workflow. Qualitative interviews with clinicians and patients provided information on feasibility, acceptability, and perceived utility.

resultsPrior to implementation, depression screening was recorded in 12% using a formal instrument; 64% were screened informally by clinical interview, and no screening was recorded in 24%. Of 1406 patients seen for follow-up care during the implementation period, 88% were screened, 59% using the GDS-15 (self-administered in 51% and interviewer administered in 8%), a nearly 5-fold increase in formal screening. Lack of clinician or staff time and inability to provide the GDS-15 to the patient ahead of the visit were the most commonly cited reasons for lack of screening using the GDS-15; 378 (45%) patients completing the GDS-15 screened positive for depression, and 137 were enrolled for a 12-month prospective follow-up. Mean GDS-15 scores improved from 8.8 to 7.0 (P < 0.0001) and the 39-item Parkinson's Disease Questionnaire emotional subscore from 42.2 to 36.7 (P = 0.0007).

conclusionsDepression screening in PD using a formal instrument can be achieved at much higher levels than is currently practiced, but there are barriers to implementing this in clinical practice. An individual site-specific process is necessary to optimize screening rates.

Indexed as

DepressionMass ScreeningParkinson DiseaseAgedAged, 80 and overFemaleHumansMaleMiddle AgedPsychiatric Status Rating Scalesdepressionmental healthParkinson's diseasescreening

Identifiers

PMID39030949
PMCPMC11489616

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.